Press Release in respect of Unaudited(Standalone & Consolidated) Financial Results for the quarter ended 30th September 2026

Date: 10th November, 2026 The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block Dalal Street Bandra - Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 544293 Scrip Symbol: SURAKSHA Dear Sir / Ma’am, Reg: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 Sub: Press release in respect of Unaudited (Standalone and Consolidated) Financial Results of the Company for quarter and half year ended September 30, 2026 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith the press release in relation to the Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter and half year ended September 30, 2026. Further, details as required to be disclosed as per BSE’s Circular No. 20230714-34 dated 14 July 2023, and NSE’s Circular No. NSE/CML/2023/57 dated 14 July 2023, are as under: Date of occurrence of Event/Information: November 10, 2026 Time of occurrence of Event/Information: 03:40 P.M. (IST) This may please be informed to all the concerned. For Suraksha Diagnostic Limited Shreya Arora Company Secretary & Compliance Officer Membership No.: 30892 Encl.: as above Suraksha Diagnostic Limited (Formerly known as Suraksha Diagnostic Private Limited) CIN: L85110WB2005PLC102265 Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India E-mail: investors@surakshanet.com I Website: www.surakshanet.com Phone:(033) 6605 9750 SURAKSHA DIAGNOSTIC LIMITED Suraksha Diagnostics Delivers Strong Q2 & H1 FY27 Performance PAT grew by 69% year-on-year in Q2 FY27 and EBITDA grew by 45% year-on-year in Q2 FY27 Kolkata, 10th Nov 2026: Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announceditsunauditedfinancialresultsforthequarterandyeartodateended30thSeptember2026. H1 FY27 Financial Performance Snapshot (Y-o-Y) Total Income EBITDA Profit After Tax EPS ₹ 1893.09 million ₹ 678.47 million ₹ 277.96 million ₹ 5.38 +24% +37% +54% + ₹1.85 Key Financial Highlights Particulars Q2 FY27 Q2 FY26 Y-o-Y H1 FY27 H1 FY26 Y-o-Y Total Income (₹ million) 1,005.75 795.80 26% 1,893.09 1,530.72 24% EBTIDA (₹ million) 363.17 249.66 45% 678.47 496.22 37% EBTIDA Margin (%) 36.7% 31.7% 36.3% 32.8% PAT (₹ million) 149.50 88.28 69% 277.96 180.03 54% PAT Margin (%) 15.1% 11.2% 14.9% 11.9% Key Operational Highlights Particulars Q2 FY27 Q2 FY26 Y-o-Y H1 FY27 H1 FY26 Y-o-Y Total tests (# million) 2.32 2.20 5% 4.42 4.13 7% Total Patients (# million) 0.42 0.38 12% 0.80 0.71 12% Tests per patient (#) 5.50 5.83 5.53 5.78 Average Revenue per test (₹) 427 357 19% 422 367 15% Average Revenue per patient (₹) 2348 2,083 13% 2335 2,120 10% SURAKSHA DIAGNOSTIC LIMITED CommentingontheresultsMs.RituMittal,JointManagingDirector&CEOsaid,- “Suraksha continued its strong growth momentum in Q2 FY27, delivering healthy growth across the business. The performance during the quarter was supported by sustained growth in patient and test volumes, alongside improving contributionsfromcentrescommissionedoverthepastfewquarters,whichareprogressivelymaturingandcontributingto theoverallgrowth. Wecontinuedtoexpandournetworkduringthequarter,openingfivenewcentres,comprisingtwohubcentresandthree spokescentres,inlinewithourstrategyofbuildingclustersandprogressivelyincreasingdensityaroundthem.Withthis,we have further strengthened our presence across West Bengal while also laying the groundwork for expansion into newer markets. Suraksha Genomics continued to focus on building its presence and strengthening its growth trajectory. While still at an early stage, we believe genomics has the potential to emerge as an increasingly meaningful contributor to our business overthecomingyears. AswemoveintothesecondhalfofFY27,weremainfocusedondrivingsustainablegrowththroughourexistingnetwork, improvingthecontributionofmaturingcentresandpursuingdisciplinedexpansionacrossnewermarkets.” AboutSurakshaDiagnosticLimited: SurakshaDiagnosticLimitedisaleadingproviderofintegratedsolutionsinpathologyandradiologytesting,aswellasmedical consultationservices,offeringaseamlessexperiencetocustomersthroughanextensiveoperationalnetwork.Thecompany isthelargestintegrateddiagnosticchainwithpresenceinthestatesofWestBengal,Bihar,AssamandJharkhand. Thecompany’scentralreferencelaboratoryisaccreditedbytheCollegeofAmericanPathologists,whilethe4laboratorieshold National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation, and the 6 advanced diagnostic centresareaccreditedbytheNationalAccreditationBoardforHospitals&HealthcareProviders(NABH). Company: Suraksha Diagnostic Limited Investor Relations: MUFG Intime India Private Limited Name: Mr. Omkar Bagwe Email: investors@surakshanet.com Email: omkar.bagwe@in.mpms.mufg.com Name: Sumeet Khaitan CIN: L85110WB2005PLC102265 Email:Sumeet.khaitan@in.mpms.mufg.com Website: https://www.surakshanet.com/ Meeting Request Link –Click Here SafeHarbor Anyforward-looking statements about expected future events, financial and operatingresults of theCompanyarebased on certain assumptions which the Company does not guarantee the fulfilment of. Past performance also should not be simply extrapolated into the future. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company’s operationsincludea downtrend in theindustry, global ordomestic orboth, significant changesin political and economic environmentinIndiaorkeymarketsabroad,taxlaws,litigation,labourrelations,exchangeratefluctuations,technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertakeanyobligationtoupdateforward-lookingstatementstoreflecteventsorcircumstancesafterthedatethereof.